Institute of Hematology and Blood Diseases, Chinese Academy of Medical Sciences, Tianjin

Institute of Hematology, Tianjin

The Institute of Hematology and Blood Diseases Hospital (IHBDH), affiliated with the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), is a premier institution dedicated to the research, diagnosis, and treatment of hematological disorders. Located at No. 288 Nanjing Road, Heping District, Tianjin, China, the hospital operates under a unified administrative structure with dual official designations.

Historical Background

Established in November 1957 by Professor Deng Jiadong, a pioneer in Chinese hematology, the institute has undergone significant transformations. In the 1970s, it relocated to Sichuan but returned to Tianjin in 1982. Today, it stands as the only tertiary specialized hospital for hematological diseases in China, integrating medical treatment, scientific research, teaching, and industry.

Facilities and Services

As a top-tier specialized hospital, IHBDH boasts 804 beds and a comprehensive range of specialized centers, including:

• Anemia Diagnosis and Treatment Center
• Leukemia Diagnosis and Treatment Center
• Thrombosis and Hemostasis Diagnosis and Treatment Center
• Stem Cell Transplantation Center
• Lymphoma Diagnosis and Treatment Center
• Myelodysplastic Syndromes (MDS) Diagnosis and Treatment Center
• Pediatric Hematology Diagnosis and Treatment Center
• Comprehensive Diagnosis and Treatment Center
• Regenerative Medicine Diagnosis and Treatment Center
• Blood Disease Emergency Center
• Critical Care Medicine Diagnosis and Treatment Center
• Hematopathology Diagnosis Center
• Clinical Testing Center

The hospital serves over 300,000 patients annually, making it a leading institution for hematological care in China.

Academic and Research Excellence

IHBDH has consistently ranked first in the China Hospital Specialty Reputation List (Hematology) for 14 consecutive years, from 2010 to 2023. The institute has undertaken more than 1,100 scientific research projects, including 460 national-level and over 350 provincial-level projects. It has received 109 awards above the provincial and ministerial levels, including 24 national awards, and has been granted 67 authorized invention patents.

The institute publishes the “Chinese Journal of Hematology” and established the English journal “Blood Science,” which has been included in the Directory of Open Access Journals (DOAJ) database and selected as a high-starting new journal in the China Science and Technology Journal Excellence Action Plan.

Clinical Trials and Innovations

IHBDH is at the forefront of clinical research, having conducted numerous clinical trials that bridge innovative research with clinical applications. Notably, the institute supported the approval of the first chimeric antigen receptor T-cell (CAR-T) therapy product (CNCT19) for acute myeloid leukemia by China’s National Medical Products Administration in 2023.

The institute has also led trials in gene therapy for hemophilia, cell therapy for beta-thalassemia, mesenchymal stem cell therapy for graft-versus-host disease and immune thrombocytopenia, and non-viral CAR-T therapy for lymphoma. As of 2023, IHBDH has been involved in 460 clinical trials for new drugs targeting hematological diseases, underscoring its leadership in clinical research.

Notable Achievements

In 2023, IHBDH’s contributions were recognized among China’s Top 10 achievements in hematology. This accolade reflects the institute’s commitment to advancing hematology research and its significant impact on clinical practices both nationally and internationally.

Leadership and Expertise

The institute is home to esteemed experts in the field of hematology, including:

• Professor Lugui Qiu: Chief Physician and Doctoral Supervisor, Director of the Lymphoma Diagnosis and Treatment Center, and Director of the Tianjin Cord Blood Hematopoietic Stem Cell Bank. He has been engaged in clinical and basic research on hematological diseases for over 30 years and is a leading figure in lymphoma research in China.
• Professor Dehui Zou: Chief Physician and Postgraduate Tutor, Assistant Director of the Lymphoma Diagnosis and Treatment Center. His research focuses on clinical and translational studies on lymphoid tumors, hematopoietic stem cell transplantation, and CAR-T cell therapies for hematological malignancies.
• Professor Gang An: Chief Physician and Master’s Supervisor, specializing in the diagnosis and treatment of plasma cell diseases and lymphomas. He has extensive research experience, including postdoctoral work at Dana-Farber Cancer Institute, Harvard University, and has published numerous papers in esteemed journals.

These experts, among others at IHBDH, contribute significantly to the institute’s reputation as a leader in hematology.

Conclusion

The Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, continues to set benchmarks in the field of hematology through its comprehensive patient care, groundbreaking research, and dedication to medical education. Its unwavering commitment to excellence solidifies its status as a cornerstone institution in China’s medical landscape.

The Institute of Hematology and Blood Diseases Hospital (IHBDH), CAMS & PUMC, offers a comprehensive range of specialties focused on the diagnosis, treatment, and research of hematological disorders. The key specialties available at the hospital include:

1. Anemia Diagnosis and Treatment Center

• Management of various types of anemia, including iron deficiency anemia, aplastic anemia, and hemolytic anemia.

2. Leukemia Diagnosis and Treatment Center

• Specialized care for acute and chronic leukemias, including AML, ALL, CML, and CLL.
• Innovative therapies such as CAR-T cell therapy and targeted drug treatments.

3. Lymphoma Diagnosis and Treatment Center

• Diagnosis and treatment of Hodgkin’s and non-Hodgkin’s lymphoma.
• Advanced immunotherapies and stem cell transplantation.

4. Myelodysplastic Syndromes (MDS) Diagnosis and Treatment Center

• Specialized in the treatment and management of MDS and its progression to leukemia.

5. Thrombosis and Hemostasis Diagnosis and Treatment Center

• Treatment of blood clotting disorders, including hemophilia, thrombophilia, and platelet function disorders.

6. Stem Cell Transplantation Center

• Bone marrow and hematopoietic stem cell transplantation for leukemia, lymphoma, and aplastic anemia.

7. Pediatric Hematology Diagnosis and Treatment Center

• Diagnosis and treatment of blood diseases in children, including leukemia, thalassemia, and inherited blood disorders.

8. Regenerative Medicine Diagnosis and Treatment Center

• Research and application of regenerative therapies, including mesenchymal stem cell therapy.

9. Comprehensive Diagnosis and Treatment Center

• Multidisciplinary approach for complex hematological cases.

10. Blood Disease Emergency Center

• Immediate care for acute hematological emergencies, including severe bleeding disorders and leukemia-related complications.

11. Critical Care Medicine Diagnosis and Treatment Center

• Specialized intensive care unit (ICU) for critically ill patients with blood disorders.

12. Hematopathology Diagnosis Center

• Advanced laboratory diagnostics for blood cancers and other hematological conditions.

13. Clinical Testing Center

• Cutting-edge diagnostic facilities for genetic, molecular, and immunological testing related to blood diseases.

IHBDH is a leading institute in China for hematology research and treatment, offering world-class medical care and pioneering new therapies, including CAR-T cell therapy, gene therapy, and stem cell transplantation.

Infrastructure of the Institute of Hematology and Blood Diseases Hospital (IHBDH), CAMS & PUMC, Tianjin

The Institute of Hematology and Blood Diseases Hospital (IHBDH) is one of China’s most advanced medical institutions dedicated to hematology. Its infrastructure is designed to support cutting-edge research, diagnostics, treatment, and patient care in hematological diseases. Below is a detailed overview of its infrastructure:

1. Hospital Facilities

• Total Area: A modern, state-of-the-art hospital complex in Tianjin, China.
• Total Beds: 804 beds, making it one of the largest hematology hospitals in the country.
• Specialized Departments: Multiple centers dedicated to different types of blood diseases, including leukemia, lymphoma, anemia, and stem cell transplantation.
• Outpatient Clinics: Equipped to handle over 300,000 patient visits annually, ensuring specialized and efficient care.
• Emergency & Critical Care: Advanced Blood Disease Emergency Center and Critical Care Medicine Center to handle life-threatening hematological emergencies.

2. Advanced Diagnostic and Laboratory Facilities

• Hematopathology Diagnosis Center:
  • High-end flow cytometry, molecular pathology, and genetic sequencing for blood disease diagnosis.
• Clinical Testing Center:
  • Equipped with high-throughput sequencing, next-generation sequencing (NGS), and PCR labs for genetic and biomarker analysis.
• Imaging & Radiology:
  • Advanced MRI, CT, PET-CT, and ultrasound facilities tailored for hematology patients.
• Blood Banking & Stem Cell Processing Unit:
  • Tianjin Cord Blood Hematopoietic Stem Cell Bank for stem cell transplantation and regenerative medicine research.

3. Stem Cell Transplantation & Regenerative Medicine Infrastructure

• Dedicated Stem Cell Transplantation Center with:
  • Multiple bone marrow transplantation (BMT) units.
  • GMP-certified clean rooms for cell processing and storage.
  • CAR-T and gene therapy manufacturing units.
  • Specialized isolation rooms to prevent infections in transplant patients.
• Regenerative Medicine Research and Therapy Unit:
  • Focuses on mesenchymal stem cell therapy, gene therapy, and novel cell therapies.

4. Clinical Research & Drug Development Infrastructure

• Clinical Trial Center:
  • Over 460 ongoing clinical trials for new hematology drugs, gene therapy, and CAR-T treatments.
  • Collaborations with global pharmaceutical companies and regulatory agencies.
• Good Manufacturing Practice (GMP) Facility:
  • Specially designed laboratories for CAR-T cell production and gene-editing research.
• Biobank & Genomic Research Lab:
  • Houses large-scale biological sample storage for hematology research.

5. Patient Care and Rehabilitation Facilities

• Specialized Wards for High-Risk Patients:
  • Negative pressure rooms for immunocompromised patients.
  • ICU for critical hematology patients.
• Outpatient and Day Care Units:
  • For chemotherapy, transfusions, and targeted therapy sessions.
• Patient Education & Rehabilitation Center:
  • Focuses on long-term recovery, nutritional guidance, and psychological support.

6. Academic and Training Facilities

• Medical Training & Teaching Center:
  • Affiliated with Peking Union Medical College (PUMC).
  • Offers postgraduate, PhD, and fellowship training in hematology.
• Conference & Seminar Halls:
  • Hosts international and national medical conferences on blood diseases.
• Library & Digital Learning Center:
  • Provides access to thousands of medical research papers, journals, and case studies.

7. Digital & Smart Hospital Features

• Electronic Medical Records (EMR) System:
  • Integrated patient data management for seamless care.
• Telemedicine & Remote Consultation:
  • Allows expert consultations for patients across China and globally.
• AI-Based Diagnostic Tools:
  • Machine-learning-powered analysis for faster and more accurate disease detection.

The Institute of Hematology and Blood Diseases Hospital (IHBDH), CAMS & PUMC is located at:

📍 Hospital Address:
No. 288 Nanjing Road, Heping District, Tianjin 300020, China

This location is in the Heping District, a central area in Tianjin, making it easily accessible for patients from across China and internationally.

Facilities at the Institute of Hematology and Blood Diseases Hospital (IHBDH), CAMS & PUMC, Tianjin

The Institute of Hematology and Blood Diseases Hospital (IHBDH) is one of China’s most advanced hospitals specializing in hematology. It offers a comprehensive range of facilities for diagnosis, treatment, research, and patient care.

1. Patient Care Facilities

• 804 Beds with specialized wards for different hematological diseases.
• Outpatient and Daycare Units for chemotherapy, transfusions, and targeted therapies.
• Emergency & Critical Care Units dedicated to handling life-threatening blood disorders.
• Isolation Wards & Negative Pressure Rooms for patients with weak immune systems, such as those undergoing stem cell transplantation.
• Blood Disease Emergency Center providing 24/7 emergency services.

2. Advanced Diagnostic & Laboratory Facilities

• Hematopathology Diagnosis Center for blood disease testing.
• Clinical Testing Center with cutting-edge diagnostic tools.
• Molecular Pathology & Genetic Testing Labs for personalized treatment plans.
• Advanced Imaging & Radiology with MRI, CT, PET-CT, and ultrasound.
• Blood Banking & Stem Cell Processing Unit for safe blood transfusions and transplantations.

3. Specialized Treatment Centers

• Stem Cell Transplantation Center with facilities for bone marrow and cord blood transplants.
• CAR-T Cell Therapy Unit for advanced immunotherapy treatments.
• Gene Therapy & Regenerative Medicine Center focusing on cutting-edge treatments.
• Comprehensive Hematology Centers for leukemia, lymphoma, MDS, anemia, and thrombosis.

4. Research & Clinical Trial Facilities

• Clinical Trial Center with over 460 active hematology trials.
• Good Manufacturing Practice (GMP) Facility for developing CAR-T and gene therapies.
• Biobank & Genomic Research Laboratory for hematology studies.
• International Collaborations & Research Partnerships with global pharmaceutical companies.

5. Academic & Training Facilities

• Medical Education & Training Center affiliated with Peking Union Medical College (PUMC).
• Postgraduate, PhD, and Fellowship Programs in hematology.
• Conference & Seminar Halls for international medical events.
• Medical Library & Digital Learning Center for continuous education.

6. Digital & Smart Hospital Features

• Electronic Medical Records (EMR) System for integrated patient care.
• Telemedicine & Remote Consultation Services for international and rural patients.
• AI-Based Diagnostic Tools to improve accuracy and efficiency in disease detection.

Conclusion

The Institute of Hematology and Blood Diseases Hospital (IHBDH) provides world-class medical infrastructure, advanced hematology treatment, and pioneering research facilities. With its focus on patient care, research, and medical education, it remains one of the leading hematology hospitals in China and globally.